Alerta

Crohn disease intestinal microbial marker, application thereof and method for constructing Crohn disease detection model

Resumen de: CN119162304A

The invention discloses a Crohn disease enteric microorganism marker and application thereof and a method for constructing a Crohn disease detection model.The Crohn disease enteric microorganism marker is characterized in that enteric microorganisms related to Crohn disease are extracted from metagenome data of samples of Crohn disease patients and healthy people; the method comprises the following steps: establishing a random forest model for diagnosing the Crohn disease through the intestinal microbial marker of the Crohn disease, and evaluating to obtain a Crohn disease detection model; according to the method provided by the invention, the treatment effect can be evaluated, the treatment scheme can be adjusted in time, and a new tool is provided for prognosis evaluation of a patient; the specific intestinal microbial marker aiming at the Crohn's disease is found and applied, so that the accuracy and effectiveness of early auxiliary diagnosis, prognosis and treatment of the Crohn's disease are improved, the understanding of the Crohn's disease is deepened, and the development of microbiomics in clinical application is promoted; new biomarkers can be found easily, and new biomarkers or therapeutic targets can be found.

ATP Engineered strains for ATP detection and use thereof

Resumen de: KR20240175341A

본 발명은 ATP의 검출능을 갖는 효모, ATP의 검출방법 및 ATP의 검출방법에 의한 염증성 장 질환 진단용 바이오마커에 관한 것으로, 본 발명의 반딧불이 루시페라제를 발현하는 재조합 효모를 기반으로 하는 ATP의 검출방법인 전세포 기반 센서 시스템을 활용하여 ATP를 쉽게 검출할 수 있고 이를 이용하여 비침습 적으로 염증성 장 질환(IBD)과 같은 ATP 관련 질병의 진단에 유용하게 활용할 수 있다.

BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITIS

Resumen de: US2024415899A1

This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.

IN VITRO MODEL OF INFLAMED INTESTINAL BARRIER

Nº publicación: WO2024256789A1 19/12/2024

Solicitante:

UNIV DE FRANCHE COMTE [FR]
UNIVERSITE DE FRANCHE COMTE

Resumen de: WO2024256789A1

The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg/ml and interleukin 8 (IL-8) at a concentration of more than 150 pg/ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg/ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg/ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.